Short Interest in OptimizeRx Corp. (NASDAQ:OPRX) Declines By 16.4%

OptimizeRx Corp. (NASDAQ:OPRX) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 1,398,242 shares, a decrease of 16.4% from the February 12th total of 1,673,046 shares. Based on an average daily volume of 364,058 shares, the short-interest ratio is presently 3.8 days. Currently, 7.9% of the shares of the company are sold short. Currently, 7.9% of the shares of the company are sold short. Based on an average daily volume of 364,058 shares, the short-interest ratio is presently 3.8 days.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $44,000. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of OptimizeRx in the fourth quarter worth $62,000. USA Financial Formulas purchased a new stake in shares of OptimizeRx during the third quarter worth $131,000. Finally, Wesbanco Bank Inc. acquired a new stake in shares of OptimizeRx in the third quarter valued at $205,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Trading Up 1.4%

OptimizeRx stock traded up $0.09 during midday trading on Tuesday, hitting $6.62. 438,326 shares of the stock were exchanged, compared to its average volume of 414,402. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. The stock’s 50-day simple moving average is $9.80 and its 200 day simple moving average is $14.26. OptimizeRx has a fifty-two week low of $5.54 and a fifty-two week high of $22.25. The stock has a market capitalization of $124.19 million, a price-to-earnings ratio of 25.46 and a beta of 1.21.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. On average, equities analysts anticipate that OptimizeRx will post -0.33 EPS for the current year.

OptimizeRx declared that its board has approved a stock repurchase program on Thursday, March 5th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of analysts recently issued reports on OPRX shares. Lake Street Capital lowered their price target on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. B. Riley Financial reiterated a “buy” rating and issued a $11.00 price objective (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Zacks Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday. Finally, Stifel Nicolaus dropped their price target on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.57.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.